Cases & Deals

Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound

Clients Kowa Company, Ltd.

Jones Day advised Kowa Company, Ltd. and its subsidiary Kowa Pharmaceuticals America, Inc. in a license agreement with CymaBay Therapeutics for exclusive U.S. rights to Arhalofenate, a compound in late stage clinical development for the treatment of gout.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.